Who is sponsoring NCT03208270?

NCT03208270 is sponsored by Policlinico Hospital.

What drugs are being tested in NCT03208270?

Interventions in NCT03208270: Antithrombin supplementation, No antithrombin supplementation.

What condition does NCT03208270 study?

NCT03208270 studies Extracorporeal Membrane Oxygenation.

Is NCT03208270 still recruiting?

NCT03208270 is currently completed. Last updated 17 May 2019.

Last reviewed 2019-05-17 · How we verify

NCT03208270

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antithrombin Supplementation in ECMO

Completed Phase 2, PHASE3 Last updated 17 May 2019

What this trial tests

Phase 2, PHASE3 trial testing Antithrombin supplementation in Extracorporeal Membrane Oxygenation in 49 participants. Completed in 15 May 2019.

Timeline

28 July 2017

Primary endpoint
15 May 2019

15 May 2019

Quick facts

Lead sponsor	Policlinico Hospital
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	49
Start date	28 July 2017
Primary completion	15 May 2019
Estimated completion	15 May 2019
Sites	1 location across Italy

Drugs / interventions tested

Antithrombin supplementation — full drug profile →
No antithrombin supplementation — full drug profile →

Conditions studied

Extracorporeal Membrane Oxygenation — all drugs for Extracorporeal Membrane Oxygenation →

Sponsor

Policlinico Hospital

Who can join

18 and older, any sex, with Extracorporeal Membrane Oxygenation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bleeding is the most feared complication during extracorporeal membrane oxygenation (ECMO) and is associated with high dosing of heparin. There is no consensus on antithrombin (AT) supplementation during ECMO. However, AT is needed by heparin to properly anticoagulate. We hypothesize that maintaining normal antithrombin levels during ECMO is associated with a less heparin dosing and more adequate level of anticoagulation.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The relationship between antithrombin administration and inflammation during veno-venous ECMO.
Panigada M, Spinelli E, De Falco S, Consonni D, et al · · 2022 · cited 12× · PMID 35995816 · DOI 10.1038/s41598-022-17227-7
Antithrombin supplementation during extracorporeal membrane oxygenation: study protocol for a pilot randomized clinical trial.
Panigada M, Spinelli E, Cucino A, Cipriani E, et al · · 2019 · cited 10× · PMID 31186035 · DOI 10.1186/s13063-019-3386-4
40th International Symposium on Intensive Care & Emergency Medicine : Brussels, Belgium. 24-27 March 2020.
· 2020 · cited 6× · PMID 32209112 · DOI 10.1186/s13054-020-2772-3
Antithrombin Supplementation during Extracorporeal Membrane Oxygenation: Study Protocol for a Pilot Randomized Clinical Trial
Panigada M, Spinelli E, Cucino A, Cipriani E, et al · · 2019 · DOI 10.21203/rs.2.62/v2

Verify or expand the search:

Other recruiting trials for Extracorporeal Membrane Oxygenation

Currently open trials in the same condition.

NCT06862700 — Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients · recruiting
NCT06560164 — Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO · NA · recruiting
NCT06369584 — Prone Position During ECMO in Pediatric Patients With Severe ARDS · NA · recruiting
NCT05574296 — Hydrogen's Feasibility and Safety as a Therapy in ECPR · Phase 1 · recruiting
NCT06660784 — Mechanism of Nitric Oxide on Ventilator-induced Diaphragm Dysfunction with Extracorporeal Membrane Lung Assistance · active not recruiting

Other Policlinico Hospital trials

Trials by the same sponsor.

NCT06848010 — TRacheal Cuff PRessure Evaluation Study · NA · not yet recruiting
NCT06583642 — Antimicrobial Therapeutic Drug Monitoring During Lung Transplant Perioperative Phase · not yet recruiting
NCT06302192 — Renal Doppler to Predict Acute Kidney Injury (AKI) in ARDS Patients. (RED-AKI Study) · not yet recruiting
NCT06312488 — Point of Care Evaluation of Fibrinolysis in Sepsis · NA · completed
NCT06395259 — Observational Study on the Variation of Ascorbic Acid in Patients Undergoing Solid Organ Transplantation · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03208270 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Policlinico Hospital
Last refreshed: 17 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03208270.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing